Hinova Pharmaceuticals Inc.

“In the following 10 to 20 years, the next R&D peak in small molecules lies in protein degradation; protein degraders will have a market worth at least $100bn,” Liqiang Fu, co-founder and chief te

Chinese biotechs are encountering investors who appear to have been balking at acquiring their new shares since early September, with one private equity funding scrapped, a re-financing deal reduced a

Chinese biotechs are rushing to raise cash through the public market as investor sentiment has improved. Shanghai-based InventisBio, Inc. , a developer of small molecule cancer and gout drugs has bec

Chinese firms Hinova Pharmaceuticals Inc. and Kintor Pharmaceutical Ltd. are racing each other to develop same-class drugs to treat patients with COVID-19, with each having candidates progressing